Affiliation:
1. Department of Pharmacology & Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USA
Abstract
Glioblastoma (GBM) is the most common malignant primary brain tumor, resulting in poor survival despite aggressive therapies. GBM is characterized by a highly heterogeneous and immunosuppressive tumor microenvironment (TME) made up predominantly of infiltrating peripheral immune cells. One significant immune cell type that contributes to glioma immune evasion is a population of immunosuppressive cells, termed myeloid-derived suppressor cells (MDSCs). Previous studies suggest that a subset of myeloid cells, expressing monocytic (M)-MDSC markers and dual expression of chemokine receptors CCR2 and CX3CR1, utilize CCR2 to infiltrate the TME. This study evaluated the mechanism of CCR2+/CX3CR1+ M-MDSC differentiation and T cell suppressive function in murine glioma models. We determined that bone marrow-derived CCR2+/CX3CR1+ cells adopt an immune suppressive cell phenotype when cultured with glioma-derived factors. Glioma-secreted CSF1R ligands M-CSF and IL-34 were identified as key drivers of M-MDSC differentiation while adenosine and iNOS pathways were implicated in the M-MDSC suppression of T cells. Mining a human GBM spatial RNAseq database revealed a variety of different pathways that M-MDSCs utilize to exert their suppressive function that is driven by complex niches within the microenvironment. These data provide a more comprehensive understanding of the mechanism of M-MDSCs in glioblastoma.
Funder
National Institutes of Health
National Center for Advancing Translational Sciences of the National Institutes of Health under University of Florida Clinical and Translational Science Awards
Florida Center for Brain Tumor Research
Reference45 articles.
1. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016–2020;Ostrom;Neuro-Oncology,2023
2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma;Stupp;N. Engl. J. Med.,2005
3. Management of Glioblastoma: State of the Art and Future Directions;Tan;CA Cancer J. Clin.,2020
4. Harnessing the Immune System in Glioblastoma;Brown;Br. J. Cancer,2018
5. DeCordova, S., Shastri, A., Tsolaki, A.G., Yasmin, H., Klein, L., Singh, S.K., and Kishore, U. (2020). Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. Front. Immunol., 11.